沈婉寄,李 晖.HER2基因变异非小细胞肺癌的治疗研究进展[J].肿瘤学杂志,2022,28(10):809-817.
HER2基因变异非小细胞肺癌的治疗研究进展
Research Progress on the Treatment of Non-small Cell Lung Cancer Harboring HER2 Alterations
投稿时间:2022-08-28  
DOI:10.11735/j.issn.1671-170X.2022.10.B003
中文关键词:  人表皮生长因子受体2  非小细胞肺癌  抗体偶联药物  靶向治疗
英文关键词:human epidermal growth factor receptor 2  non-small cell lung cancer  antibody-drug conjugates  targeted therapy
基金项目:
作者单位
沈婉寄 温州医科大学 
李 晖 中国科学院大学附属肿瘤医院(浙江省肿瘤医院)中国科学院基础医学与肿瘤研究所 
摘要点击次数: 183
全文下载次数: 5
中文摘要:
      摘 要:目前,针对肺癌少见驱动基因突变的治疗仍是非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗的热点和难点。与经典突变相比,人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)变异的NSCLC患者对传统化疗及非选择性酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)反应欠佳。近年来,以新型选择性TKIs和抗体偶联药物(antibody-drug conjugates,ADCs)为代表的新兴治疗策略深刻改变了HER2变异NSCLC的治疗格局。全文对HER2变异晚期NSCLC患者的治疗进展与挑战作一综述。
英文摘要:
      Abstract: At present,targeting rare driver variants in non-small cell lung cancer(NSCLC) remains the hotspots and challenge. Compared with canonical mutations,NSCLC patients with human epidermal growth factor receptor 2(HER2) alterations show worser response to chemotherapy and non-selective tyrosine kinase inhibitors(TKIs). The treatment landscape has dramatically changed in recent years owing to the exploring of novel therapeutic strategies represented by novel selective TKIs and antibody-drug conjugates(ADCs). This article reviews the treatment progress and challenges of advanced NSCLC patients with HER2 alterations.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器